# Global significance test based on quantile regression with applications to genomic studies of Alzheimer’s disease > **NIH NIH R21** · UNIVERSITY OF LOUISVILLE · 2022 · $190,247 ## Abstract Project Summary/Abstract Alzheimer's disease (AD) is one of the leading causes of death for the elderly with no current cure. Genomics studies, such as mapping expression quantitative trait loci (eQTL) and differential gene expressions, play a critical role in understanding the biological mechanisms of AD and developing potential therapeutic treatments. In genomics studies, there has been growing awareness that the covariates (e.g., quantitative gene expression) may have changing effects on the distribution of responses (e.g., disease phenotypes) reflecting a heterogeneous covariates-response association. Those heterogeneous associations shed insight on scientific discoveries and entail significant implications but are often neglected by most existing analysis procedures confined to a narrow aspect of the response distribution (e.g., standard linear regression focusing on the mean or quantile regression at a single quantile level). Thus, the development of valid and efficient hypothesis tests to detect heterogeneous associations is of great value to genomics studies of complex diseases such as AD. This proposal aims to develop several quantile regression-based global significance tests, which utilize all information across a well-chosen region of quantile levels and provide researchers with evaluations of the overall impacts of covariates on the response. Inspired by our preliminary data analysis on the two studies of aging and dementia, namely Religious Orders Study (ROS) and Memory and Aging Project (MAP), we will first propose a global significance test to thoroughly evaluate covariates' impact across all quantile levels of the response variable (Aim 1). Then motivated by high-dimensional genomics data of AD in ROS/MAP, we will further develop two global significance tests for high-dimensional responses and covariates data, respectively (Aim 2). Moreover, we will apply the proposed tests in Aims 1-2 to the genomics data generated by ROS/MAP to identify eQTL and differentially expressed genes that can be used to prioritize risk genes of AD for identifying developing potential treatments (Aim 3). We will also provide a user-friendly R package to implement the proposed tests. The innovation of our proposal is three-fold. (i) By evaluating the impacts of covariates on responses across the entire quantile domain, the proposed global significance tests have a superior power to identify heterogeneous covariates-response associations compared to alternative methods. (ii) As the proposed tests neither impose any stringent model assumption nor require additional splines smoothing or re-sampling or shrinkage estimation, they can be broadly implemented in large-scale genomics data. (iii) Our proposed test in Aim 2 will serve as a useful tool for detecting heterogeneous associations between covariates and multiple responses. The successful completion of this project will facilitate detecting heterogeneous associations and the subsequent scientific discoveries in A... ## Key facts - **NIH application ID:** 10465282 - **Project number:** 5R21AG070659-02 - **Recipient organization:** UNIVERSITY OF LOUISVILLE - **Principal Investigator:** Qi Zheng - **Activity code:** R21 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2022 - **Award amount:** $190,247 - **Award type:** 5 - **Project period:** 2021-09-01 → 2025-05-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10465282 ## Citation > US National Institutes of Health, RePORTER application 10465282, Global significance test based on quantile regression with applications to genomic studies of Alzheimer’s disease (5R21AG070659-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10465282. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*